Maide Cavalli

Maide Cavalli

Auto-generated profile, based on publicly available information

Maide Cavalli

Division of Hematology, AOU "Policlinico-Vittorio Emanuele", Catania, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Alessandra RomanoAlessandra Romano
Alessandra Romano
CCConcetta Conticello
Concetta Conticello
MCMaide Cavalli
Maide Cavalli
CVCalogero Vetro
Calogero Vetro
AFAlessia La Fauci
Alessia La Fauci
FRFrancesco Di Raimondo
Francesco Di Raimondo
Multiple Myeloma (MM) is a systemic hematologic disease due to uncontrolled proliferation of monoclonal plasma cells (PC) in bone marrow (BM). Emerging in other solid and liquid cancers, the host immune system and the microenvironment have a pivotal role for PC growth, proliferation, survival, migration, and resistance to drugs and are responsible for some clinical manifestations of MM. In MM, microenvironment is represented by the cellular component of a normal bone marrow together with extracellular matrix proteins, adhesion molecules, cytokines, and growth factors produced by both stromal cells and PC themselves. All these components are able to protect PC from cytotoxic effect of chemo- and radiotherapy. This review is focused on the role of immunome to sustain MM progression, the emerging role of myeloid derived suppressor cells, and their potential clinical implications as novel therapeutic target.

25 November 2013 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
FMFortunato Morabito
Fortunato Morabito
SBSara Bringhen
Sara Bringhen
Alessandra LaroccaAlessandra Larocca
Alessandra Larocca
PWPierre Wijermans
Pierre Wijermans
María Victoria MateosMaría Victoria Mateos
María Victoria Mateos
Massimo OffidaniMassimo Offidani
Massimo Offidani
Novel agents in combination with melphalan and prednisone (MP) significantly improved progression‐free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty‐six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2‐microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P = 0.007). After a median follow‐up of 34 months (range, 1–92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52–0.82; P < 0.001) and OS (median 79.7 vs. 45.1 months, HR 0.44; 95% CI 0.32–0.59; P < 0.001) in comparison with MPT. The benefit in terms of OS of the VMP group was quite similar among patients with different risk factors defined by sex, ISS, ECOG performance status, or serum creatinine but not among patients ≥75 years. Multivariate analysis confirmed that VMP was an independent predictor of longer PFS and OS. In a control‐case matched analysis, PFS and OS were prolonged in patients who received VMP in comparison with those treated with MPT. Am. J. Hematol. 89:355–362, 2014.

19 May 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Alessandra RomanoAlessandra Romano
Alessandra Romano
CCConcetta Conticello
Concetta Conticello
MCMaide Cavalli
Maide Cavalli
CVCalogero Vetro
Calogero Vetro
CRCosimo Di Raimondo
Cosimo Di Raimondo
FRFrancesco Di Raimondo
Francesco Di Raimondo
During the past decade, overall results of treatment of multiple myeloma (MM) have been improved and survival curves are now significantly better with respect to those obtained with historical treatment. These improvements are linked to a deeper knowledge of the biology of disease and to the introduction in clinical practice of drugs with different mechanism of action such as proteasome inhibitors and immunomodulatory drugs (IMiDs). However, MM remains in most cases an incurable disease. For patients who relapse after treatment with novel agents, the prognosis is dismal and new drugs and therapeutic strategies are required for continued disease control. In this review, we summarize new insights in salvage therapy for relapsed/refractory MM as emerging from recent clinical trials exploring the activity of bendamustine, new generation proteasome inhibitors, novel IMiDs, monoclonal antibodies, and drugs interfering with growth pathways.